



Destiny Rezendes @dezzie_rezzie

Aug 9 • 21 tweets • [dezzie_rezzie/status/1689373850985697280](https://twitter.com/dezzie_rezzie/status/1689373850985697280)

1  The Bill & Melinda Gates Foundation [BMFG] is a name that cannot be mentioned when discussing the Covid-19 pandemic. Although not a doctor nor was he a politician, Bill Gates' impact was monumental. He funded Baric's lab at UNC Chapel Hill. He was close with Dr. Fauci..



NEWS RELEASE 14-SEP-2006

UNC receives \$21.3 million Gates Foundation grant

[Grant and Award Announcement](#)

UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL

CHAPEL HILL -- The University of North Carolina at Chapel Hill has received a \$21.3 million grant from the Bill & Melinda Gates Foundation to develop effective, inexpensive drugs to treat late-stage African sleeping sickness and visceral leishmaniasis -- diseases that infect and kill hundreds of thousands of people in developing nations.

The grant supports the work of an international consortium led by Dr. Richard Tidwell, a professor in UNC's Schools of Medicine and Pharmacy and principal investigator for the project.

Committed grants

University of North Carolina at Chapel Hill

[Grantee website](#)  Chapel Hill, North Carolina, United States

Purpose

(FAMILI2) Fetal Age and Machine Learning Initiative Part 2

Division
Gender Equality

Date
NOVEMBER 2019

Region served

Committed amount
\$2,133,290



 <https://www.gatesfoundation.org/about/committed-grants/2019/11/inv003266>

University of North Carolina at Chapel Hill | Bill & Melinda Gates ...

\$2,133,290. Grant topic. MNCH Discovery and Tools. Duration (months) 29. Grantee location. Chapel Hill, North Carolina, United States. More about our work. Our story. Learn about the origins of the foundation and the values that drive our work. Learn more. Our work.

 <https://www.gatesfoundation.org/about/committed-grants/2018/11/inv-007382>

University of North Carolina at Chapel Hill | Bill & Melinda Gates ...

Committed grants. More in this section Committed grants. Home; About; Committed grants ... University of North Carolina at Chapel Hill Grantee website Chapel Hill, North Carolina, United States Purpose (LABOR) Limiting Adverse Birth Outcomes in Resource-Limited Settings Grantee. Division. Gender Equality ... 1991-2023 Bill & Melinda Gates ...



2  Gates had purchased immense power in the world of Public Health-founding/funding; GAVI, IAVI, Global Polio Eradicate Initiative GPEI, WHO, CDC, ResearchGate, Global Health Investment Fund & the OECD, Trinity Challenge, GinkoBioworks & In 2000 Gates started the ONE Campaign.



Building global commitment to fight poverty and disease

In the fight against extreme poverty, hunger, and preventable disease around the globe, ONE plays a unique role. It uses its resources to make human crises and their solutions matter—to leaders, funders, private and public institutions, and millions of people worldwide.

[visit ONE](#)

[follow @ONECampaign](#)

[read blog posts about ONE](#)

ONE pursues its goals through policy advocacy, grassroots mobilization, communications, and creative campaigning. Among its more visible efforts are direct personal appeals by high-profile individuals—including ONE co-founder Bono—to world leaders to address urgent development issues and follow through on their aid commitments. ONE also mobilizes its 3.2 million members to pressure policymakers to increase their effort, accountability, and transparency in the fight against disease and poverty, particularly in Africa. By making the most of technology and social media, **ONE has also become a leading force in educating the public about global health** and development and in changing perceptions about aid and its impact.

ONE's Roots

ONE originated in conversations between Bill Gates and Bono in the early 2000s about the need to better inform Americans about extreme poverty around the world. Together with Melinda Gates, Bobby Shriver, George Soros, Ed Scott, Bob Geldof, and Jamie Drummond, they created an anti-poverty advocacy organization called DATA that focused on deploying celebrities and other influential individuals to urge world leaders to take action on specific development issues. Within a few years, DATA had joined with several other organizations to form ONE, with major backing from the Bill & Melinda Gates Foundation. The goal was to create a political constituency for development priorities—particularly the UN Millennium Development Goals, which in 2000 set specific global targets to address disease, poverty, and other pressing development issues.

Investors & Partners

LEADERSHIP

BOARD

INVESTORS & PARTNERS

SCIENTIFIC ADVISORY COMMITTEE (SAC)

JOINT COORDINATION GROUP (JCG)

PORTFOLIO STRATEGY & MANAGEMENT BOARD (PSMB)

CEPI'S COMMITMENT TO TACKLING RACISM

ANTI-SLAVERY AND HUMAN TRAFFICKING STATEMENT

CEPI was founded in Davos by the governments of Norway and India, the Bill & Melinda Gates Foundation, Wellcome, and the World Economic Forum.

To date, CEPI has secured financial support from Australia, Austria, Belgium, the Bill & Melinda Gates Foundation, Canada, Denmark, the European Commission, Ethiopia, Finland, Germany, Greece, Hungary, Iceland, Indonesia, Italy, Japan, Kuwait, Lithuania, Luxembourg, Malaysia, Mexico, Netherlands, New Zealand, Norway, Panama, Portugal, Philippines, Romania, Saudi Arabia, Senegal, Serbia, Singapore, Switzerland, Republic of Korea, United Kingdom, USA, and Wellcome.

CEPI has also received support from private sector entities as well as public contributions through the [UN Foundation COVID-19 Solidarity Response Fund](#).

Close collaboration with our partners is crucial for the success of our work.

See our [full list of contributions and pledges](#).

DAVOS WEF

Bill Gates: My 'best investment' turned \$10 billion into \$200 billion worth of economic benefit

PUBLISHED WED, JAN 23 2019-7:13 AM EST | UPDATED WED, JAN 23 2019-10:28 AM EST

Matthew J. Belvedere
@MATT_BELVEDERE

SHARE    

KEY POINTS

- Investing in global health organizations aimed at increasing access to vaccines creates a 20-to-1 return, the Microsoft co-founder and philanthropist says.
- Putting \$10 billion into the S&P 500 would have grown only to \$17 billion.

3  The ONE Campaign was about...Global Health! [of course] and was formed w/ Bobby Shriver, George Soros, & others & used celebrities like Bono and Lady Gaga to promote it. All of it in alignment with the UN Millennium Development Goals

Leadership

Board of Directors

ONE's Board of Directors includes individuals with extensive experience in advocacy and activism, policy, politics and business. The board oversees ONE's work and helps to ensure we are making progress against our mission.

ONE consists of [two separate non-profit organizations](#), The ONE Campaign (501(c)(3)) and ONE Action (501(c)(4)). The goal of the ONE Campaign is to raise public awareness and educate policy makers about the importance of smart and effective policies and programs. The goal of ONE Action is to urge the public and policy makers to take action, which includes lobbying.

**BONO**

Lead singer, U2
Co-founder, ONE and
(RED)

**SUSAN A.
BUFFETT**

Chair, The Sherwood Foundation and the
Susan Thompson Buffett Foundation

**THE RT HON
DAVID CAMERON**

Former Prime Minister of
the United Kingdom



ONE Receives \$3 Million from Bill & Melinda Gates Foundation

December 4 2004

WASHINGTON – Leading political advisors Mark McKinnon and Mike McCurry joined with 11 relief and development agencies that make up ONE to announce a new national effort to mobilize Americans in support of helping fight global AIDS and poverty.

Underlining the bipartisan support for helping the poorest people in the world, the campaign released results of a national poll showing a large majority of Americans believe it is important for the United States to start a major new initiative to fight global AIDS and poverty.

Share



Looking for something?

[Jobs](#)
[Safeguarding](#)
[Contact](#)
[Unsubscribe](#)
[Sitemap](#)
[Privacy](#)

Media Contacts

Global Media Director

Ben Maitland
ben.maitland@one.org
+44 7881 370 441

NORTH AMERICA

4 In 2017 the BMGF along w/ Wellcome Trust, WEF, Norway & India, founded the Coalition of Epidemic Preparedness [CEPI] at Davos. Now Headquartered in Oslo, Norway. CEPI is a lead promoter of "OneHealth."

CEPI also plans to progress its work on developing vaccines for known threats, such as chikungunya, Lassa virus, and Nipah virus. Heymann welcomes this news but thinks CEPI could have more of a One Health approach, considering both animal and human vaccines. "I think it's important that there be a One Health area in CEPI as well. In issues such as Lassa, it may be that a rodent vaccine would be more appropriate than a human vaccine", he says. Development of an animal vaccine might also be more appropriate for MERS-CoV. Koopmans agrees that with MERS-CoV "you could also look at the animal side. Studies have shown if you bring all these animals together for racing, for gatherings, that's where you find a lot of circulation, that's when you find human health risk, so you could also think of developing vaccines at least for the racing industry".

One of the big moonshot ideas in CEPI's plan is to compress vaccine development timelines to 100 days. Saville highlights the speed of success of COVID-19 vaccine development as "really quite remarkable" but notes opportunities for improvement. She explains that by compressing different areas of the vaccine development pipeline you can reduce the timelines further. For example, "you can compress the times by having things like clinical trial networks and clinical protocols in place that people can agree on in advance", she says.

CEPI also wants to produce a library of prototype vaccines against representative

pathogens from critical and familiar. Saville notes that CEPI's work with



September 2013, New York

5  BMFG alongside JP Morgan Chase Bank founded the Global Health Investment Fund which works alongside the Global Health Investment Corporation in 2012, a founder of GHIC is also CEO for GHIF, long time corporate lawyer, and IAVI board member, Labeeb Abboud

what specific types of COVID-19 programs have GHIF portfolio companies launched

[Quick Search](#)

GHIF portfolio companies have launched several types of COVID-19 programs. Here are some examples:

- Rapid COVID-19 tests: Atomo Diagnostics and AccessBio, both GHIF portfolio companies, have developed rapid COVID-19 tests that provide results in just minutes ^{① ②}. These tests have been approved for use in several countries and are being used to help diagnose COVID-19 infections.
- CRISPR-based diagnostic test: GeneDrive, another GHIF portfolio company, is working on developing a CRISPR-based diagnostic test for COVID-19 ^③. The test would be able to detect the virus in saliva samples and provide results in just 30 minutes.
- Low-cost COVID-19 vaccine: Univercells, a GHIF portfolio company, is working on developing a low-cost COVID-19 vaccine that can be produced quickly and at scale ^④. The vaccine uses a technology called microfluidics to produce the vaccine in small, portable units that can be easily transported and deployed in low-resource settings.
- Other COVID-19-related programs: GHIF portfolio companies have also launched other COVID-19-related programs, although specific details are not provided in the search results. These programs may include the development of COVID-19 treatments, the production of personal protective equipment (PPE), or the deployment of other medical solutions to help address the pandemic.

Overall, GHIF portfolio companies have launched a range of COVID-19 programs, including rapid tests, diagnostic tests, vaccines, and other medical solutions. These programs demonstrate GHIF's commitment to investing in innovative technologies that have the potential to make a significant impact on global health outcomes, including in the context of the COVID-19 pandemic.

 Global Health Investment Corporation

[About](#) [Portfolio](#) [Partners](#) [News](#) [Careers](#)

Global Health Investment Fund

Our namesake \$108 million social impact fund (GHIF) invested in twelve companies developing clinical diagnostics, devices, vaccines, and therapeutics targeting diseases that disproportionately burden people living in low- and middle-income countries, such as HIV/AIDS, malaria, tuberculosis and cholera. The fund's portfolio companies have successfully commercialized more than a dozen products that have been delivered to over 100 million people.

GHIF was started by Bill Gates & JP Morgan Chase



History

Inspired by Innovation

In 2012, the Bill & Melinda Gates Foundation sponsored the creation of GHIC and the launch of its initial fund, the Global Health Investment Fund, with the support of JP Morgan Chase. The original vision was to apply well-established venture capital practices using blended finance to accelerate the development of products and technologies that would improve lives globally by addressing high-burden global health challenges.



Driven by Collaboration

The Government of Germany, acting through the German Federal Ministry for Economic Cooperation and Development (BMZ) and the KfW Development Bank, helped capitalize GHIC with an initial grant and remains a key strategic partner and funder of GHIC.

Other GHIF stakeholders and investors include Grand Challenges Canada, the Swedish International Development Agency, the International Finance Corporation, GSK, Merck, Pfizer, AXA Investment Managers, Storebrand, JP Morgan Social Finance, the Children's Investment Fund Foundation, along with other foundations and individual investors.

Since its launch, GHIF's success has inspired the launch of other impact investment funds, many with GHIC's support and collaboration.

Preventing Future Threats

In 2021, GHIC entered into a 10-year venture investment partnership with the Biomedical Advanced Research and Development Authority (BARDA) focused on global health security. BARDA will provide GHIC with funding, as well as scientific and technical input, and GHIC will mobilize additional third-party capital to finance the development of technologies to respond to or prevent future pandemics and other health security threats.



Global Health
Investment
Corporation

"We invest in global health because we know that when health improves, life improves by every measure." – Bill Gates, Co-chair, Bill & Melinda Gates Foundation

Partners

Our strategic partners and investors include leading philanthropic, public, and private sector institutions. Together, we're improving global public health and investing in a healthier, safer world.

KfW Federal Ministry for Economic Cooperation and Development
Bank aus Verantwortung

MITRE

KfW →

KfW Development Bank has been helping the German Federal Government to achieve its goals in development policy and international development cooperation for more than 50 years. On behalf of the German Federal Ministry for Economic Cooperation and Development (BMZ), KfW Development Bank helps its partners, including GHIC, to improve global health, accelerate the development of medicines, vaccines and diagnostics for neglected infectious diseases, and catalyzing additional investment in these areas.

Global Health
Investment
Corporation

DRIVE

BILL & MELINDA GATES FOUNDATION

MITRE

KfW →

KfW Development Bank has been helping the German Federal Government to achieve its goals in development policy and international development cooperation for more than 50 years. On behalf of the German Federal Ministry for Economic Cooperation and Development (BMZ), KfW Development Bank helps its partners, including GHIC, to improve global health, accelerate the development of medicines, vaccines and diagnostics for neglected infectious diseases, and catalyzing additional investment in these areas.

Global Health
Investment
Corporation

BARDA Ventures →

BARDA Ventures extends BARDA's core principle of public-private partnerships to the investment community, creating, for the first time at the U.S. Department of Health and Human Services, a venture-style partnership that can make quick, agile investment decisions and de-risk pharmaceutical development so that they can address unmet medical needs. Under the partnership, BARDA works with and provides financial support to GHIC to accelerate the development of medical countermeasures that address gaps in health security as well as meet commercial market needs.

BILL & MELINDA GATES FOUNDATION →

The Bill & Melinda Gates Foundation's mission is to create a world where every person has the ability to live a healthy, productive life. The Foundation seeks to spur innovation to improve the human condition, strengthen global collaboration to save and transform lives around the world, create market incentives for life-saving products by governments, foundations, and the private sector, treatments, diagnostics and other tools for those most in need, and generate high-quality data and evidence to drive progress. The Foundation recently established the Global Health Investment Fund, its inaugural Global Health Investment Fund.

CHILDREN'S INVESTMENT FUND FOUNDATION

Grand Challenges Canada

IIFC

Sida

gsk

MERCK

The Pfizer Foundation

AXA Investment Managers

JPMorganChase

storebrand

6️⃣ Abboud isn't the only name of interest at GHIC, as thee is also a former FTX member on the board [that's reassuring smh] More importantly, CEPI has massive conflicts of interest, besides board members like Richard Hatchett and Jane Halton there's the Joint Coordination Group-



LABEEB ABBoud
General Counsel & Senior Vice President
Business Development & Strategy; Corporate Secretary

Labeeb M. Abboud provides leadership on legal affairs, business development, intellectual property, risk management, and innovative finance initiatives. He advises the Board of Directors and CEO on governance and strategy, and is board chair of the IAVI-UVRI HIV Vaccine Program in Uganda. He is principally responsible for structuring IAVI's collaborations and joint ventures with academic, industry, and public sector partners to ensure that any HIV vaccine developed will be globally accessible and affordable.

Abboud is Chairman of the Board of the Global Health Investment Fund, a Bill & Melinda Gates Foundation-sponsored social impact investment fund focused on accelerating late-stage development of vaccines, drugs, diagnostics, and devices to address global health challenges in developing countries. He also serves on the Expert Advisory Group of the Medicines Patent Pool, which seeks to increase access to HIV, viral Hepatitis C, and tuberculosis treatments in low- and middle-income countries.

Prior to joining IAVI in 2004, he had 20 years of experience in the fields of international law and finance. He is a member of the Council on Foreign Relations, and has also served on the boards of several non-profit organizations. He is a graduate of Wesleyan University and Georgetown University Law Center.



As of December 2017

Members of the Scientific Advisory Committee

Alan D. Barrett
University of Texas Medical Branch

Alash'le Abimiku
International Research Center of Excellence, Institute of Human Virology, Nigeria/
University of Maryland School of Medicine Institute of Human Virology

Azra Ghani
Imperial College London, UK

Marco Safadi
Santa Casa de Sao Paulo School of Medical Sciences, Brazil

Michael King
University of Virginia (SAC Vice Chair)

Michel De Wilde
MDW Consultant, LLC

Paula Bryant
National Institute of Allergy and Infectious Diseases, National Institutes of Health, USA

Peter Dull
Bill & Melinda Gates Foundation

Peter Paradiso
Paradiso Biologics Consulting LLC

Christian Drosten
Charité – Universitätsmedizin Berlin, Germany

Dominique Maugeais
RH Solutions

Dr Emmanuel Hanon
Viome (SAC Chair)

Phil Krause
World Health Organization

Rebecca Grais
Pasteur Network

Gary Nabel
ModeX Therapeutics

George Gao
Chinese Center for Disease Control and Prevention/ Institute of Microbiology, CAS

Inger Damon
Centers for Disease Control and Prevention USA/ Emory University

Peter Smith
London School of Hygiene & Tropical Medicine

Stanley Plotkin
Emeritus Professor, University of Pennsylvania, USA

Josie Golding
Wellcome

Ken J. Ishii
International Vaccine Design Center, The Institute of Medical Science, The University of Tokyo

Sani Aliyu
Cambridge University Hospitals Foundation Trust

Rino Rappuoli
Fondazione Biotecnopolo di Siena

Vineeta Bal
Indian Institute of Science Education and Research, Pune, India

V. Krishna Mohan
Bharat Biotech, India

Laura Palomares
Instituto de Biotecnología, Universidad Nacional Autónoma de México (UNAM) (SAC Vice Chair)

Lina Wang
Duke-NUS Medical School, Singapore

Stephen Thomas
SUNY Upstate Medical University, USA

Luciana Borio
Arch Venture Partners

Mahmudur Rahman
GHD|EMPHNET

Marc Lipsitch
Harvard T.H. Chan School of Public Health USA


Vaseeharan Sathiyamoorthy
World Health Organization

Board

CEPI is a Norwegian Association. The primary governing body is the Board, which has 12 voting members (four investors and eight independent members representing competencies including industry, global health, science, resource mobilisation, finance) and five observers.



The Board is advised on decisions, such as prioritising pathogens and selecting development partners, by our Scientific Advisory Committee.



Global Health Investment Corporation

Kathryn Swan

Operations & Administration Associate

Kathryn provides operational & administration support across GHIC, including assisting the firm's executive, operations and investment teams and serving as a liaison with external stakeholders. Previously, she worked at the FTX Foundation as a Charitable Partnerships Associate where she advocated for biosecurity and AI safety in charitable giving. Additionally, she completed multiple fellowships in Effective Altruism from the Stanford University chapter and has a background in government, business, and philanthropy. Kathryn graduated with a B.A. in International Affairs and a minor in Business from the University of Colorado Boulder.

FTX employee

FTX Trading Ltd.

	FTX
Type	Private
Industry	Cryptocurrency
Founded	May 2019; 4 years ago
Founders	Sam Bankman-Fried Gary Wang ^[1]
Fate	Chapter 11 bankruptcy
Headquarters	Nassau, New Providence, The Bahamas
Key people	John J. Ray III, CEO ^[2]
Products	Cryptocurrency exchange - cryptocurrencies
Revenue	▲ US\$1.02 billion (2021) ^[3]
Operating income	▲ US\$272 million (2021) ^[3]
Net income	▲ US\$388 million (2021) ^[3]
Number of employees	c. 300 (2022) ^[4]

7 CEPI's Joint Coordination Group includes; the European Medicines Agency, GAVI, UNICEF, FDA, WHO, & World Bank. CEPI's Scientific Advisory Committee which includes; Christain Drosten, China's CDC director George Gao, Stanley Plotkin [wrote the literal book on "Vaccines,"



Scientific Advisory Committee (SAC)

The Scientific Advisory Committee is an independent body within the CEPI governing structure that provides world-class scientific support, advice, and guidance to CEPI staff and the CEPI Board in responding to the current COVID-19 pandemic.

They also deliver guidance and challenge towards CEPI's [US\\$3.5bn plan](#) to mitigate or even dramatically reduce the threat of future pandemics and epidemics. Final decision-making about the issues addressed by the committee rests with CEPI staff or the Board.

CEPI Joint Coordination Group

The current members of the Joint Coordination Group include:

- The African Vaccine Regulatory Forum (AVAREF)
- **Developing Countries Vaccine Manufacturers Network (DCVMN) member**
- **European Medicines Agency (EMA)**
- FIND, the global alliance for diagnostics
- **Gavi, the Vaccines Alliance**
- The Global Fund
- International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) member
- International Federation of Red Cross and Red Crescent Societies (IFRC)
- **Médecins Sans Frontières (MSF)**
- **UNICEF**
- **US Food and Drug Administration (FDA)**
- **Wellcome Trust**
- **World Bank**
- **World Health Organization (WHO)**



Investors & Partners

CEPI was founded in Davos by the governments of Norway and India, the Bill & Melinda Gates Foundation, Wellcome, and the World Economic Forum.

To date, CEPI has secured financial support from Australia, Austria, Belgium, the Bill & Melinda Gates Foundation, Canada, Denmark, the European Commission, Ethiopia, Finland, Germany, Greece, Hungary, Iceland, Indonesia, Italy, Japan, Kuwait, Lithuania, Luxembourg, Malaysia, Mexico, Netherlands, New Zealand, Norway, Panama, Portugal, Philippines, Romania, Saudi Arabia, Senegal, Serbia, Singapore, Switzerland, Republic of Korea, United Kingdom, USA, and Wellcome.

CEPI has also received support from private sector entities as well as public contributions through the [UN Foundation COVID-19 Solidarity Response Fund](#).

Close collaboration with our partners is crucial for the success of our work.

See our [full list of contributions and pledges](#).

CEPI

Timothy Grant Evans

Timothy Evans joined McGill University in September 2019 as the Inaugural Director and Associate Dean of the School of Population and Global Health (SPGH) in the Faculty of Medicine and Associate Vice-Principal (Global Policy and Innovation). He joined McGill after a 6-year tenure as the Senior Director of the Health, Nutrition and Population Global Practice at the World Bank Group.



From 2010 to 2013, Dr. Evans was Dean of the James P. Grant School of Public Health at BRAC University in Dhaka, Bangladesh, and Senior Advisor to the BRAC Health Program. From 2003 to 2010, he was Assistant Director General at the World Health Organization (WHO). Prior to this, he served as Director of the Health Equity Theme at the Rockefeller Foundation. Earlier in his career he was an attending physician of internal medicine at Brigham and Women's Hospital in Boston and was an Assistant Professor in International Health Economics at the Harvard School of Public Health.

Dr. Evans has been at the forefront of advancing global health equity and strengthening health systems delivery for more than 20 years. At WHO, he led the Commission on Social Determinants of Health and oversaw the production of the annual World Health Report. He has been a co-founder of many partnerships, including the Global Alliance on Vaccines and Immunization (Gavi), as well as efforts to increase access to HIV treatment for mothers and innovative approaches to training community-based midwives in Bangladesh.

Dr. Evans received his medical degree from McMaster University in Canada and was a Research and Internal Medicine Resident at Brigham and Women's Hospital. He earned a DPhil in Agricultural Economics from the University of Oxford, where he was a Rhodes Scholar.

George Fu Gao

Avril Haines

Avril Haines is a Senior Research Scholar at Columbia University; a Senior Fellow at the Johns Hopkins University Applied Physics Laboratory; a member of the National Commission on Military, National, and Public Service; and a principal at WestExec Advisors.



During the last administration, Dr. Haines served as Assistant to the President and Principal Deputy National Security Advisor. She also served as the Deputy Director of the Central Intelligence Agency and Legal Adviser to the National Security Council.

Dr. Haines received her bachelor's degree in physics from the University of Chicago and a law degree from Georgetown University Law Center. She serves on a number of boards and advisory groups, including the Nuclear Threat Initiative's Bio Advisory Group, the Board of Trustees for the Vodafone Foundation, and the Refugees International Advisory Council.

Jane Halton

Matthew J. Harrington

Martin Knuchel

Eduardo Martinez

8. It is worth noting that George Gao, who is China's CDC Director who was one of only 15 "players" at Event 201 in Fall of 2019 [hosted by WEF, BMGF, and Johns Hopkins] & is a two time board member for the Global Health Preparedness Monitoring Board is also CEPI.

JOHNS HOPKINS
BLOOMBERG SCHOOL
of PUBLIC HEALTH

Center for
Health Security

WHO WE ARE OUR WORK EDUCATION & TRAINING RESOURCES

IN THIS SECTION HOME > OUR WORK > TABLETOP EXERCISES > EVENT 201

TABLETOP EXERCISE
Event 201

This training tabletop exercise is based on a fictional scenario. The inputs experts used for modeling the potential impact of a severe pandemic were used for the Event 201 exercise. It is a teaching and training resource for public health and government officials.

The Johns Hopkins Center for Health Security in partnership with the World Economic Forum and the Bill and Melinda Gates Foundation hosted Event 201, a high-level pandemic exercise on October 18, 2019, in New York, NY. The exercise illustrated areas where public/private partnerships will be necessary during the response to a severe pandemic in order to diminish large-scale economic and societal consequences.

[Statement about nCoV and our pandemic exercise](#)

In recent years, the world has seen a growing number of epidemic events, amounting to approximately 200 events annually. These events are increasing, and they are disruptive to health, economies, and society. Managing these events already strains global capacity, even absent a pandemic threat. Experts agree that it is only a matter of time before one of these epidemics becomes global—a pandemic with potentially catastrophic consequences. A severe pandemic, which becomes “Event 201,” would require robust coordination among countries, industries, national

→ About
→ Players
→ Recommendations
→ Resources
→ Videos
→ Photos
→ Media
→ Contact

Players

The following prominent individuals from global business, government, and public health were experts tasked with leading the policy response to a fictional outbreak scenario in the Event 201 tabletop exercise:

Latoya D. Abbott
Sofia Borges
Brad Connell
Chris Elias
Timothy Grant Evans
George Fu Gao
Avril Haines
Jane Halton
Matthew J. Harrington
Martin Knuchel
Eduardo Martinez
Stephen C. Redd
Hasti Taghi
Lavan Thiru
Adrian Thomas

George Fu Gao

Professor George F. Gao is the Director-General, Chinese Center for Disease Control and Prevention; a Professor in the Institute of Microbiology, Chinese Academy of Sciences; President of the Chinese Society of Biotechnology; and President of the Asian Federation of Biotechnology (AFOB).

Dr. Gao obtained his DPhil degree from Oxford University, UK, and did his postdoc work in both Oxford University and Harvard University, with a brief stay in Calgary University. His research interests include enveloped viruses and molecular immunology. His group research is mainly focused on the enveloped virus entry and release, especially influenza virus interspecies transmission (host jump), structure-based drug-design, and structural immunology. He is also interested in virus ecology, especially the relationship between influenza virus and migratory birds or live poultry markets and the bat-derived virus ecology and molecular biology.

Dr. Gao has published more than 450 refereed papers and 10 books or book chapters, and he has applied for and obtained more than 25 UK, US, and Chinese patents. His research has recently expanded to public health policy and global health strategy. He led the China CDC team from September to November 2014 to work in Sierra Leone in the fight against Ebola.

Dr. Gao is a member (academician) of the Chinese Academy of Sciences, a fellow of the Third World Academy of Sciences (also known as the World Academy of Sciences), a fellow of the American Academy of Microbiology, and an associate member of EMBO. He is a recipient of several national and international awards, including the TWAS Medical Prize (2012), the Nikkei Asian Prize (2014), and the HLHL S&T Advancement Award (2015).



GPMB Terms of Reference

Why was the GPMB created?

The GPMB was established in 2018 as a high-level platform for political advocacy, in recognition of the severe health and economic costs of failing to adequately prepare for and manage disease outbreaks for countries and communities globally. The global response to many previous health emergencies had shown that the world was caught in a cycle of panic and neglect. The Board was tasked with providing an assessment of the state of the world's preparedness, including successes, challenges, progress and gaps, and with advocating for the changes needed for a safer world.

Co-Chairs and Board Members **Former Co-Chairs and Board Members**

Co-Chairs



Dr Gro Harlem Brundtland >

Former Prime Minister of Norway and former WHO Director-General



Mr Elhadj As Sy >

Former Secretary General of the International Federation of the Red Cross and Red Crescent Societies

Board Members



Dr Anthony S. Fauci >

Director, National Institute of Allergy and Infectious Diseases, USA



Sir Jeremy Farrar >

Interim GPMB Co-Chair and Director of Wellcome



Dr George F. Gao >

Director-General, Chinese Center for Disease Control and Prevention (China CDC)



H.E. Sigrid Kaag >

Minister for Foreign Trade and Development Cooperation, The Netherlands

9 Two other JCG members at CEPI are Linfa Wang, a fellow bat expert w/ Shi Zeng Li. Wang is a UC Davis grad. The other is Luciana Borio; CFR member, Johns Hopkins Grad, & the CIA's venture fund, In-Q-Tel's, VP & inspiration for Resilience Inc/Moderna

<https://t.co/gSppzWKKtf>



Destiny Rezendez 

@dezzie_rezzie · [Follow](#)

Replying to @dezzie_rezzie

Resilience has acquired an insane \$1.9 billion from just 4 funding rounds & in as little as 25months! How is that possible? Other than the gains made in acquisitions, Resilience itself was practically handed \$800 million at its inception. Why? Luciana Borio...

BORIO 

• Council of Foreign Relations
• Championed the partnership between the BMGF & the FDA.
• All US was advisor on biodefense programs (2001 to 2008)

Following 9/11 and the Anthrax Attacks of 2001, ESSENTIAL policies were implemented that have DIRECTLY led to the bio-medical atmosphere we have today. Funding for Bio-warfare increased by \$1 billion dollars and in 2003-2004 Bush signed into law the Project Bioshield.

The anthrax attacks, as well as the September 11, 2001 attack, spurred significant increases in U.S. government funding for biological warfare countermeasures. The anthrax attacks increased funding for the new vaccines and drugs. ^[10] These included the monoclonal antibody raxibacumab, which treats anthrax as well as an Anthrax Vaccine Adjuvant, both of which are developed by the US government. ^[11]

RESILIENCE 

• U.S. FOOD & DRUG ADMINISTRATION
• CONFFLICTS OF INTEREST
• Backed by investors with an unmatched record of success

CONFFLICTS OF INTEREST
- Both sit on the board of ARCH
- One of the founders of In-Q-Tel
- Scott Gottlieb was in the FDA. So was Borio & Mark McClellan
- Scott also is in NEA
- Deltavir is a subsidiary of BVC
- David Schenck is in GV

Over 1/2 of these pictured attended the SALT conferences

Luciana I. Borio 

From: Luciana I. Borio
Senior Advisor to Biden Admin

Public Health Threats and Pandemics - Pharmaceutical and Vaccines - Biotechnology - Infectious Diseases - Homeland Security - Health

Expert Bio

Luciana Borio is a senior expert for global health at the Council on Foreign Relations. She also is a senior advisor at Anthrax, a startup that provides venture-stage venture capital for technology firms in information technology, life sciences, and physical sciences. Dr. Borio specializes in biodefense, emerging infectious diseases, medical product development, and complex public health emergencies.

businesswire 

HOME SERVICES NEWS EDUCATION ABOUT US

Nanotherapeutics Announces Name Change to Ology Bioservices, Reflecting the Company's Ongoing Transformation into One of the Top Contract Development and Manufacturing Organizations of Vaccines and Biologics

October 02, 2017 08:33 AM Eastern Daylight Time

ALACHUA, Fla.--(BUSINESS WIRE)--Nanotherapeutics, Inc. today announced that the Company has changed its name to Ology Bioservices, Inc., effective immediately. The name change is part of a broader rebranding effort and directly reflects the Company's evolution into a leading provider of contract development and manufacturing organizations (CDMOs), with differentiated expertise in biologics and vaccines, with its broad service offering. Ology Bioservices is building a commercial client base consisting of leading companies focused on research and development of biologics and vaccines for both preventive and therapeutic use.

4:55 AM · Mar 4, 2023

 17   

This biologist helped trace SARS to bats. Now, he's working to uncover the origins of COVID-19

Linfa Wang's innovative new assay could help reveal when and where the virus spilled over to humans

30 SEP 2020 • BY KAI KUPFERSCHMIDT

RS COMMENTARY JOURNALS ▾

COVID-19

Science

6



Wang, who heads the Emerging Infectious Diseases Program at Duke-NUS Medical School in Singapore, immediately got to work developing a new assay that can detect antibodies against SARS-CoV-2 in blood samples—an indication of prior infection. The tool could help untangle how the pandemic began. So far, the evidence is that the virus originated in bats, animals Wang has long argued are uniquely suited to harboring viruses that pose a danger to humans. Now, he hopes his assay can help trace the path of the virus to humans and pinpoint when and where it first spilled over.

The work is a natural next chapter for Wang, who has been tracking viruses from bats to humans for more than 2 decades. Marion Koopmans, a virologist at Erasmus Medical Center, credits him for essentially launching the field of bat immunology and developing the tools to pursue it. "He has made a heroic effort to establish a very challenging research line, which needed to start from scratch," she says.

10  I've covered Borio and Linfa Wang in the past & their involvement cannot be understated. What's interesting is to see Borio in multiple articles in early 2020 in NEMJ, & JAMA that were co-authored by Jesse Goodman, a Georgetown univ grad & husband to Nicole Luire.

Nicole Lurie

[Add language](#)

[Article](#) [Talk](#)

[Read](#) [Edit](#) [View history](#) [Toc](#)

From Wikipedia, the free encyclopedia

You have a new message (last change).

Nicole Lurie is an American physician, professor of medicine, and public health official. During the administration of President Barack Obama, she was Assistant Secretary for Preparedness and Response (ASPR) at the United States Department of Health and Human Services (HHS) from 2009 through the end of the president's second term. The mission of the Office of the Assistant Secretary for Preparedness and Response is to "lead the nation in preventing, responding to and recovering from the adverse health effects of public health emergencies and disasters, ranging from hurricanes to bioterrorism."^[1]

Education [\[edit\]](#)

Lurie received her bachelor's degree from the University of Pennsylvania and her M.D. from the University of Pennsylvania Medical School in 1979.^{[1][2]} Lurie received her Master of Science in Public Health from the University of California, Los Angeles (UCLA), where she also completed her medical residency.^[1] Lurie was a Robert Wood Johnson Foundation Clinical Scholar at UCLA.^[1]



Nicole Lurie

Personal details
Education University of Pennsylvania (BS, MD)
(University of California, Los Angeles)

In 1998, Lurie took leave from her position in Minnesota to become Principal Deputy Assistant Secretary for Health in the U.S. Department of Health and Human Services, holding this position until 2001. In this role, Lurie worked on the Healthy People 2010 initiative and initiative to reduce health disparities, as well as pandemic influenza planning.^[2]

After leaving HHS, Lurie became senior natural scientist and the Paul O'Neill Alcoa Professor of Health Policy at the Arlington, Virginia-based Rand Corporation, a think tank.^{[2][3]} Lurie directed the organization's Center for Population Health and Health Disparities and oversaw its work on public health and preparedness.^[2] Lurie testified before the Subcommittee on Bioterrorism and Public Health Preparedness of the Senate Committee on Health, Education, Labor and Pensions in March 2006, explaining that "her work included evaluating public health preparedness in California and Georgia; conducting 32 tabletop exercises on hypothetical crises caused by smallpox, anthrax, botulism, plague, and pandemic influenza; and interviewing officials from 44 communities in 17 states."^{[2][4]}

In July 2009, Lurie returned to HHS as Assistant Secretary for Preparedness and Response at the Department of Health and Human Services. In that position, Lurie oversaw the federal public health response to various health crises, including Hurricane Sandy and the Boston Marathon bombing.^[2] Lurie is also a rear admiral of the U.S. Public Health Service.^[1] Lurie was also appointed to oversee the federal response to the Flint water crisis.^[5]

While serving as assistant secretary at HHS, Lurie also practiced medicine at the Bread for the City clinic in Washington, D.C.^{[1][2]}

Personal life [\[edit\]](#)

Lurie is married to Dr. Jesse L. Goodman, a physician and now the chief scientist at the Food and Drug Administration; the two met while at the University of Pennsylvania. They have three sons.^[2]

12  Lurie's husband, Jesse Goodman- former CBER director, & FDA chief Scientist, on the board for GSK, the United States Pharmacopeia [USP] which sets standards for health care products in the U.S recognized as official by the federal government and are enforceable by the FDA.

What is the focus of Nicole Lurie's work at CEPI

Quick Search

Nicole Lurie, MD, MPH |
AME - Academic Medica...

Nicole Lurie - CEPI |
cepi - 2

Nicole Lurie, MD, MPH |
The Commonwealth Fun...

CEPI appoints former
Assistant Secretary for...

Former Assistant
Secretary for...

cepi - 5

Nicole Lurie Named Penn
LDI Distinguished Health...

upennin - 6

CEPI appoints former

Assistant Secretary for...

homelandprepre...

homelandprepre...

homelandprepre...

Nicole Lurie is connected to several organizations in her career. Here are the organizations she is connected to:

1. **World Bank:** Nicole Lurie is currently a consultant to the World Bank. Her role in this capacity is not specified in the search results.
2. **Coalition for Epidemic Preparedness Initiatives (CEPI):** Lurie is connected to CEPI and holds multiple roles within the organization. She is the Executive Director for Preparedness and Response at CEPI and also serves as the Director of CEPI-US.
3. **United States Department of Health and Human Services (HHS):** Lurie served as the Assistant Secretary for Preparedness and Response (ASPR) at HHS during the administration of President Barack Obama. In this role, she provided leadership in preventing, responding to, and recovering from the adverse health effects of public health emergencies and disasters.
4. **Bread for the City clinic:** While serving as the assistant secretary at HHS, Lurie also practiced medicine at the Bread for the City clinic in Washington, D.C.
5. **Society of General Internal Medicine:** Lurie was elected to the council of the Society of General Internal Medicine in 1987 and served as its president from 1997 to 1998.
6. **Institute of Medicine:** Lurie is a member of the Institute of Medicine. The Institute of Medicine is now known as the National Academy of Medicine.

These organizations highlight Lurie's involvement in public health, emergency preparedness, and healthcare policy at both national and international levels.

U.S. Pharmacopeia (USP)

Jesse L. Goodman, M.D., M.P.H.

Medical Sciences Trustee



Having served as President of the USP Convention during the 2015-2020 cycle, Dr. Jesse Goodman will help guide USP as it begins its third century of promoting and protecting public health. In his role as Medical Sciences Trustee on USP's board, Dr. Goodman will apply his knowledge of USP along with his personal and professional experience as the organization rises to the challenges of the global supply chain and helping to ensure ongoing access to quality medicines for people around the world.

His day-to-day experiences as a practicing clinician coupled with the knowledge that he gained during years with FDA have given Dr. Goodman an appreciation for the need for balanced and collaborative approaches to regulations and what that could do to keep our drug and food supply as safe and effective as possible.

Dr. Goodman is the Director of the Center on Medical Product Access, Safety and Stewardship and attending physician at Georgetown University and DC Veterans Administration Hospitals. Until 2014, Dr. Goodman was FDA's Chief Scientist, leading crosscutting scientific efforts, including public health preparedness and medical countermeasures. Prior to that, Dr. Goodman directed FDA's Center for Biologics Evaluation and Research, supporting innovative regulatory approaches to vaccines and other biologics and spearheading unique public-private efforts to address public health challenges. As Senior Advisor to the Commissioner, he initiated the first U.S. Task Force on Antimicrobial Resistance. Having served on the World Health Organization's Ebola Vaccine Working Group, Dr. Goodman helped develop the Global Vaccine Action Plan. He is currently on the Centers for Disease Control and Prevention's Board of Scientific Counselors (Infectious Diseases).

A Harvard graduate, Dr. Goodman received his M.D. from Albert Einstein College of Medicine and completed postdoctoral training at the University of Pennsylvania and UCLA, where he was Chief Resident. He has been elected to the Institute of Medicine of the National Academy of Sciences.

Georgetown University Medical Center

About the Medical Center Anti-Racism & Racial Justice Research Education Patient Care News & Events [Giving](#)

HSRI [Home](#) [GUMC Stories](#) [Georgetown's Jesse Goodman Leads Vaccine Analysis Team](#)

Georgetown's Jesse Goodman Leads Vaccine Analysis Team

Posted in [GUMC Stories](#) | Tagged [community outreach](#), [COVID-19](#), [pandemic](#), [public health](#), [vaccination](#), [Vaccine](#)

(May 7, 2021) — If you've read news stories this past year about COVID-19 vaccines in The Washington Post or The New York Times, for example, or have heard stories on NPR, the journalists' reporting may well have been informed by input from a group of vaccine experts led by Georgetown infectious disease specialist Jesse Goodman, MD, MPH.

Among the many lessons learned early on in the coronavirus pandemic was that clear, accurate and unbiased communication is critical. In 2020, inconsistent messaging from government officials contributed to skepticism about best practices to reduce the risk of infection, including vaccination.

"In the fall, when much controversy was swirling and pressure on the FDA from the White House was fierce, there was palpable and constant concern about COVID-19 vaccine development, review and authorization, and about the vaccines themselves," Goodman notes.

To begin addressing these issues, Goodman, a former FDA chief scientist and now professor of medicine and infectious diseases at Georgetown University Medical Center, and John D. Grabenstein, RPh, PhD, of the Immunization Action Coalition, formerly head of the U.S. Department of Defense's immunization programs, formed COVAT, the **COVID-19 Vaccine Analysis Team**.

To fill out the COVAT roster, they assembled 10 volunteer experts — including former government leaders — with expertise in clinical trials, vaccine safety, vaccination programs, virology, the regulatory process and health communications.



Jesse Goodman, MD, MPH

13  Goodman has also been on the boards for WHO, CDC, NIH, & like his wife, Lurie, he too sat on the board for CEPI. Goodman and CIA darling Borio authored many narrative based articles in early 2020 but why? Turns out they share roles together at COVAT

14  COVAT= COVID-19 Vaccine Analysis Team, ran by Georgetown University & it began September 25th 2020. Alongside Borio & Goodman are influential names like, Paul Offit, Walter Orenstein, and Vaxophile Peter Hotez-all to give pro-vaccine guidance.

Georgetown University Medical Center

About the Medical Center Anti-Racism & Racial Justice Research Education Patient Care News & Events [Giving](#)

HSRI [Home](#) [GUMC Stories](#) [Georgetown's Jesse Goodman Leads Vaccine Analysis Team](#)

Georgetown's Jesse Goodman Leads Vaccine Analysis Team

Posted in [GUMC Stories](#) | Tagged [community outreach](#), [COVID-19](#), [pandemic](#), [public health](#), [vaccination](#), [Vaccine](#)

(May 7, 2021) — If you've read news stories this past year about COVID-19 vaccines in The Washington Post or The New York Times, for example, or have heard stories on NPR, the journalists' reporting may well have been informed by input from a group of vaccine experts led by Georgetown infectious disease specialist Jesse Goodman, MD, MPH.

Among the many lessons learned early on in the coronavirus pandemic was that clear, accurate and unbiased communication is critical. In 2020, inconsistent messaging from government officials contributed to skepticism about best practices to reduce the risk of infection, including vaccination.

"In the fall, when much controversy was swirling and pressure on the FDA from the White House was fierce, there was palpable and constant concern about COVID-19 vaccine development, review and authorization, and about the vaccines themselves," Goodman notes.

To begin addressing these issues, Goodman, a former FDA chief scientist and now professor of medicine and infectious diseases at Georgetown University Medical Center, and John D. Grabenstein, RPh, PhD, of the Immunization Action Coalition, formerly head of the U.S. Department of Defense's immunization programs, formed COVAT, the **COVID-19 Vaccine Analysis Team**.

To fill out the COVAT roster, they assembled 10 volunteer experts — including former government leaders — with expertise in clinical trials, vaccine safety, vaccination programs, virology, the regulatory process and health communications.



Jesse Goodman, MD, MPH

"Our experts include former FDA, CDC, White House, DOD and HHS scientific leaders, leading academic experts from around the country, and media and public health experts," Goodman says. "We've all worked together in some capacity over the years."

COVAT's blue-ribbon panel of experts include a former commissioner of health for New York City, the former directors of both the Office of Vaccines Research and Review and the Division of Epidemiology at FDA, the former director for medical and biodefense preparedness at the National Security Council, the previous director of the National Vaccine Program Office at HHS, the former communications director for the CDC, and two leading academic vaccine developers.

[View a List of COVAT Members](#)

Mary Bassett, MD, MPH, François-Xavier Bagnoud Professor of the Practice of Health and Human Rights, director of the François-Xavier Bagnoud Center for Health and Human Rights; former commissioner of health for New York City

Norman Baylor, PhD, president and CEO, Biologics Consulting; former director of FDA's Office of Vaccines Research and Review

Lucian Borio, MD, vice president In-Q-Tel; former director for Medical and Biodefense Preparedness at the National Security Council; former FDA acting chief scientist

M. Miles Braun, MD, MPH, adjunct professor, Georgetown University School of Medicine; former director of FDA's Division of Epidemiology

Bruce Gellin, MD, MPH, president, Global Immunization, Sabin Vaccine Institute; former deputy assistant secretary for health and director of the National Vaccine Program Office, U.S. Department of Health and Human Services

Jesse L. Goodman, MD, MPH, COVAT chair; professor of medicine and infectious diseases, Georgetown University; former FDA chief scientist and former director of the FDA Center for Biologics Evaluation and Research

John D. Grabenstein, RPh, PhD, COVAT co-chair; colonel, U.S. Army (retired); editor for Immunization Action Coalition; general manager of Vaccine Dynamics; former global executive director of medical affairs, Merck Vaccines; former senior scientist and director for U.S. Department of Defense military immunization program

Peter Hotez, MD, PhD, dean, National School of Tropical Medicine; professor of pediatrics and molecular virology & microbiology, Baylor College of Medicine; director, Texas Children's Hospital Center for Vaccine Development

Glen Nowak, PhD, strategic communications advisor to COVAT; director, Center for Health and Risk Communication; professor of advertising, University of Georgia; former director of media relations at CDC and communications director for CDC's National Immunization Program

Paul A. Offit, MD, director, Vaccine Education Center; professor of pediatrics, division of infectious diseases, Children's Hospital of Philadelphia; Hilleman Professor of Vaccinology, Perelman School of Medicine, University of Pennsylvania

Walter A. Orenstein, MD, professor of medicine, epidemiology, global health and pediatrics, Emory University; associate director, Emory Vaccine Center; director, vaccine policy and development; former deputy director, Immunization Programs, Gates Foundation; former director, CDC National Immunization Program

Link: <https://gumc.georgetown.edu/gumc-stories/georgetowns-jesse-goodman-leads-vaccine-analysis-team/#>



Bio and Featured Works

Teaching

Grants, Awards, Honors, Patents

A graduate of Harvard, Dr. Goodman received his M.D. from the Albert Einstein College of Medicine and did residency and fellowship training in Medicine, Infectious Diseases and Oncology at the Hospital of the University of Pennsylvania and at the University of California in Los Angeles (UCLA), where he was also Chief Medical Resident. Prior to his government service, he was Professor of Medicine and Chief of Infectious Diseases at the University of Minnesota where his laboratory isolated and characterized *Anaplasma phagocytophilum*, the etiologic agent of granulocytic anaplasmosis, then a newly recognized tick-borne disease.

He has served on numerous Advisory Boards and Committees for organizations including the CDC, NIH, and WHO, and helped develop the R and D section of the Global Vaccine Action Plan. He previously served on the Scientific Advisory Board of the Coalition on Epidemic Preparedness Innovations (CEPI) and currently is a Member of CDC's Board of Scientific Counselors. In 2015, he was elected volunteer President and Board member of the United States Pharmacopeia, a non-profit standards setting organization working to advance safety and quality of medicines and foods globally. In 2016, he joined the Board of GSK, chairing its Science Committee, and in 2018 the Board of Intellia Therapeutics. He has been elected to the American Society for Clinical Investigation and to the National Academy (Institute) of Medicine of the National Academy of Sciences, where he is a longstanding member of its Forum on Microbial Threats.

Language(s)

Spanish (Speak Read)

Link COVAT: <https://www.policeforum.org/covid4mar21>

what is georgetown university's COVAT, the COVID-19 Vaccine Analysis Team?

Quick Search

COVID4Mar21 - Police Executive Research... policeforum · 1

COVID-19 Vaccine Information - Consortiu... consortiu · 2

Georgetown's Jesse Goodman Leads Vaccin... GU georgetown · 3

Top Vaccine Experts Join Forces to Provide... GU georgetown · 4

Meet Our Experts - COVAT covatnow · 5

Expert Perspectives on COVID-19 Vaccination fo... nih · 6

Answer

COVAT, the COVID-19 Vaccine Analysis Team, is a group affiliated with Georgetown University Medical Center that provides objective analysis and perspectives on COVID-19 vaccine data. The team is chaired by Dr. Jesse L. Goodman, a former FDA Chief Scientist and professor of medicine and infectious diseases at Georgetown University. COVAT consists of a group of vaccine experts committed to generating unbiased analysis and serving as a trusted source of science-based communications. Their goal is to provide objective perspective and analysis as COVID-19 vaccine data emerges. The team's expertise and analysis contribute to the understanding and evaluation of COVID-19 vaccines, helping to inform public health decision-making and communication efforts.

15  In prior threads I have covered the alarming connection between Moderna's C19 jab and the CIA, namely Borio via Nat'l Resilience, as well as Georgetown's decades long health agendas.. <https://t.co/U7rP8ixuke>

 **Destiny Rezendez** 
@dezzie_rezzie · [Follow](#)

Replying to @dezzie_rezzie

13  Originally, the bio-surveillance programs, now entrusted to DHS, appeared under the name Project ARGUS GLOBAL which created the still active BioWatch program. ARGUS wasn't solely in the hands of DHS but partnered with Georgetown University



Global Argus

Project ARGUS Global

History

Approach

What We Don't Do

3:39 AM · Jun 25, 2023

 25   [Read 1 reply](#)



Destiny Rezendes [@dezzie_rezzie](#) · [Follow](#)



Replying to @dezzie_rezzie

19 What better way to infiltrate hostile countries than to gather intelligence through the humanitarian efforts of globally beneficial science? So USAID continued its efforts and Georgetown stayed on the policy side of the matter.



3:39 AM · Jun 25, 2023



23 [Reply](#) [Copy link](#)

[Read 2 replies](#)

16 As I've gone over before Georgetown Univ is one of the biggest purveyors of global health surveillance systems & often at the behest of the CIA/DoD. Not only is Goodman a professor, but so is EcoHealth's William Karesh, Katz, & Carlin, & as was recently announced Dr. Fauci.



University News

Dr. Anthony Fauci To Join Georgetown Faculty as Distinguished University Professor

June 26, 2023 |

After dedicating 54 years of his life to public service, Dr. Anthony Fauci has chosen Georgetown University to play a major role in the next phase of his career.

As a Distinguished University Professor at Georgetown, Fauci will participate in medical and graduate education and engage with students.

"I am delighted to join the Georgetown family, an institution steeped in clinical and academic excellence with an emphasis on the Jesuit tradition of public service," Fauci said. "This is a natural extension of my scientific, clinical and public health career, which was initially grounded from my high school and college days where I was exposed to intellectual rigor, integrity and service-mindedness of Jesuit institutions."

University News

5 Questions for Dr. Fauci on Why He Decided To Join Georgetown



How Jesuit Education Influenced Dr. Fauci

Fauci's Catholic upbringing and Jesuit education left an imprint on his career trajectory and approach to medicine and public service. He graduated from Regis High School in New York City in 1958 and the College of the Holy Cross in 1962 — two Jesuit institutions that cultivated intellectual rigor and service to others, he said.

Link: <https://www.georgetown.edu/news/dr-anthony-fauci-to-join-georgetown-faculty-as-distinguished-university-professor/>

CENTER for GLOBAL HEALTH SCIENCE & SECURITY

About Us People Our Work Health Diplomacy Training Initiative Events How to End a Pandemic Publications Join Us Contact

Biosafety Research

The Elizabeth R. Griffin Program focuses on strengthening the evidence base for implementing biosafety, biosecurity, and occupational health programs for the workers on the frontlines of laboratory research and health security.

Biosafety and One Health poster presented at the 15th International CDC Biosafety Symposium.

Infection prevention and control, biosafety, and biosecurity: intersections and gaps in the context of One Health

Matthew R. Boyce, Erin M. Sorrell, Claire J. Standley, Julie E. Fischer

Center for Global Health Science & Security, Elizabeth R. Griffin Program, Georgetown University

INTRODUCTION

The Global Health Security Agenda calls on nations to strengthen their capacities to detect emerging disease threats rapidly, while advancing infection prevention and control (IPC) and biosafety measures to prevent unintended disease transmission. The One Health approach emphasizes the interconnectedness of human, animal, and environmental health, and workers may already be in place to support training and resource management. As the world shifts disease surveillance strategies away from disease building capacities from the bottom up, as seen during the COVID-19 pandemic, the gaps between the three pillars of biosafety, biosecurity, and IPC are less clear. In the case of animal disease detection, environmental and animal workers in disciplines not traditionally engaged in IPC and biosafety may not be fully aware of the role they play in the prevention of disease.

OBJECTIVES

To characterize the evidence base for implementing complementary IPC and biosafety practices in the One Health context, and to identify gaps in the evidence base for community workers who might be occupationally exposed to zoonotic diseases.

METHODOLOGY

We identified titles and keywords associated with 11 categories of studies related to biosafety, biosecurity, and IPC for field workers. We then searched the PubMed and EIDSR databases for studies that met the following criteria: 1) English language, 2) published in the last 10 years, 3) human subjects, 4) following terms: occupational health, safety, or risk, disease detection, zoonotic disease transmission, prevention or control, or biosafety.

We excluded any publications that solely reviewed, summarized, or discussed the concepts of biosafety, biosecurity, or IPC, or made descriptive observations (e.g., reviews and commentaries), and case studies with animals.

RESULTS

Our search identified 143 results matching our criteria. After eliminating duplicates and reviews, commentaries, and summaries of existing guidance, we identified 84 studies. Over half of these studies (42) evaluated knowledge, beliefs, values, perceptions, and behaviors related either to occupational health or biosafety. The remaining 42 studies evaluated the implementation of IPC and biosafety practices in clinical or laboratory settings. Only one study was identified that focused on animal workers, and of these only one was related to zoonotic disease detection. The remaining 40 studies focused on the role of zoonotic pathogen exposure (ZPEA, n = 40 total). All 40 animal worker studies examined populations outside of the United States.

Figure 1. Search Results

Figure 2. Primary Purpose of Publication

Figure 3. Occupational Setting

Figure 4. Geographic Distribution

GEORGETOWN UNIVERSITY Georgetown University Medical Center

CENTER for GLOBAL HEALTH SCIENCE & SECURITY

About Us People Our Work Health Diplomacy Training Initiative Events How to End a Pandemic Publications Join Us Contact

Q Search ☰ Menu

First International Global Health Security Conference (GHS 2019)

In the wake of the 2014 West African Ebola outbreak, the international spread of Zika, the ongoing transmission of antimicrobial resistance, and the ever-present threat of another influenza pandemic, global health security has taken on a new level of importance. Multiple commissions and high-level panels have been held, recommendations have been issued, and governments, international organizations, civil society, and private industry have all committed to various initiatives aimed at improving health outcomes. Even so, significant challenges remain. In this context, [Rebecca Katz](#) and Adam Kamradt-Scott – with the assistance of the Organizing Committee ([Matthew Boyce](#) and Felix Rothery), the Steering Committee, and the Scientific Committee – convened the first [International Global Health Security Conference \(GHS 2019\)](#)



Link: <https://ghss.georgetown.edu/ghs2019/#>

17  Not only is GU entrenched in all the aforementioned affiliations but Georgetown is a huge player in the "One Health" agenda. So much so that they convened the first International Global Health Security Conference (GHS 2019) making OneHealth a focus.

<https://t.co/IvwVbkbL6Zghs2019.com/index.php>

GEORGETOWN UNIVERSITY Georgetown University Medical Center

CENTER for GLOBAL HEALTH SCIENCE & SECURITY

About Us People Our Work Health Diplomacy Training Initiative Events How to End a Pandemic Publications Join Us Contact

Q Search ☰ Menu

One Health National Systems Assessments

Overview

The CGHSS team has developed a published methodology for assessing national and sub-national systems for communication and coordination between sectors for prevention and control of priority zoonotic diseases. Piloted in Jordan and Egypt in 2013-2014, the team has since worked with the governments of Algeria, Iraq, and Guinea to implement the method and assist with One Health capacity building, in line with the International Health Regulations (2005) and Joint External Evaluation process. The methodology combines a collaborative, consensus-driven zoonotic disease prioritization step, involving government partners and other relevant partners, with a systems "maturity" that uses the identified priority zoonoses as case studies to explore the existing linkages and gaps in coordination between human, animal, and environmental health at all levels of the health systems. The case study approach allows for a robust and detailed evaluation, grounded in real-life examples, of the processes supporting disease prevention, surveillance, diagnosis, case management, and response between and within sectors.

Publications

Sorrell EM, El Arzhi M, Marwah N, Kornblit S, Standley CJ, Katz RS, Aban I, Fischer JE. (2015) [Mapping of networks to detect priority zoonoses in Jordan](#). *Front. Public Health*, 3, 219. doi: 10.3389/fpubh.2015.00219

 Center for Global Health Science and Security
Medical Dental Building, NW 306
3600 Reservoir Road NW
Washington DC 20007
Phone: 202-687-9823
Email: cgss@georgetown.edu

<https://onehealthday.com/content/one-health-day-georgetown-school-medicine>

One Health Day with Georgetown School of Medicine | One Heal...

We will be hosting a day of awareness for One Health on the Georgetown School of Medicine Campus. Events: 4:30-5:30 Just us for a pre-event with wine and appetizers in the Lobby ... Georgetown University School of Medicine Infectious Disease and One Health Interest Group Coordinator: Ms Melissa Baker Date: Monday 04 November 2019 Location:

CENTER for GLOBAL HEALTH SCIENCE & SECURITY

Q Search ≡ Men

About Us People Our Work Health Diplomacy Training Initiative Events How to End a Pandemic Publications Join Us Contact

Biosafety Research

The Elizabeth R. Griffin Program focuses on strengthening the evidence base for implementing biosafety, biosecurity, and occupational health programs for the workers on the frontlines of laboratory research and health security.

Biosafety and One Health poster presented at the 15th International CDC Biosafety Symposium.

Infection prevention and control, biosafety, and biosecurity: intersections and gaps in the context of One Health

Matthew R. Royce, Erin M. Sornell, Claire J. Standley, Julie E. Fischer
Center for Global Health Science & Security, Elizabeth R. Griffin Program, Georgetown University

INTRODUCTION

The Global Health Security Agenda calls on nations to strengthen their capacity to detect emerging disease threats, while adapting infection prevention and control (IPC) and biosafety measures to prevent unintended exposures in healthcare or laboratory settings. Most frameworks for IPC/biosafety focus on building capacities from the top down, starting with the advanced health facilities and reference laboratories where risks are recognized and controlled. However, the evidence base for how to implement these measures in the context of One Health, where healthcare facilities and primary care clinics are often the first line of defense against disease transmission, is less clear. This poster presents the results of a systematic review of the evidence on disease prevention, biosafety, and primary health care in One Health settings, with a focus on how to implement IPC and biosafety measures to prevent disease transmission in a primary care setting.

OBJECTIVES

To characterize the evidence base for implementing complementary IPC and biosafety practices in the One Health context, including the evidence base for preventing and addressing infectious disease transmission among healthcare providers, patients, and the community.

METHODOLOGY

We identified titles and keywords associated with 11 categories of infectious diseases and 10 categories of occupational health risks. We then searched the PubMed and STATA databases for the most recent publications (2010-2020) that included at least one of these keywords plus any of the following terms: infection prevention, biosafety, or prevention of infectious disease transmission, prevention, or control, or biosafety.

We excluded all publications that only reviewed, summarized, or evaluated existing evidence. We also excluded publications with descriptive dimensions (i.e., reviews and commentaries, and case reports).

Our team identified 143 studies meeting our criteria. After eliminating duplicates and screening, 103 studies were included in the final analysis. One-half of these studies (42) included knowledge, beliefs, values, perceptions, and behaviors related either to occupational health or to the prevention of infectious disease transmission among healthcare workers. A small number of studies documented the outcomes of implementing IPC or biosafety measures in One Health settings. The remaining 51 studies were excluded because they did not include the outcome of disease prevention, biosafety, or prevention of infectious disease transmission, prevention, or control, or biosafety.

RESULTS

Our team identified 143 studies meeting our criteria. After eliminating duplicates and screening, 103 studies were included in the final analysis. One-half of these studies (42) included knowledge, beliefs, values, perceptions, and behaviors related either to occupational health or to the prevention of infectious disease transmission among healthcare workers. A small number of studies documented the outcomes of implementing IPC or biosafety measures in One Health settings. The remaining 51 studies were excluded because they did not include the outcome of disease prevention, biosafety, or prevention of infectious disease transmission, prevention, or control, or biosafety.

Figure 1. Search Results

Figure 2. Primary Purpose of Publication

Figure 3. Occupational Setting

Figure 4. Geographical Distribution

The banner features a graphic of a globe with a red and orange brick pattern on the left side. The text "Global Health Security 2019" is prominently displayed in large, bold, black letters. Below the main title, the location "International Convention Centre Sydney 18-20 June 2019" is written in a smaller, black font. To the right, there is a call to action "Follow us on twitter @GHS2019conf" with a blue Twitter icon. Further down on the right, the text "Progress to date, opportunities for the future." is displayed in red, followed by the website "www.ghs2019.com". The background of the banner is a blurred image of a city skyline.

18  So why is this important? Because CEPI is pushing to 100 days to make vaccines agenda, which is being pushed into; EU, WHO, UN, & CDC. OneHealth is in the WHO treaty & IHR amendments and soon will be enacted. Both are EcoHealth Alliance & BMGF creations. Do YOU trust them?

link: <https://apps.who.int/iris/bitstream/handle/10665/336838/PMC7652556.pdf?sequence=1>

News

William Karesh: championing “One Health”

Preventing and responding to pandemics requires an integrated approach to human, animal and environmental health. William Karesh talks to Andréa Azevedo Soares.

2020

Q: How did you become interested in the interface between human and animal health?

A: You could say it started with the animals. I grew up outside a small city in coastal South Carolina where there was a lot of wildlife. I would find orphaned baby animals and raise them. That turned into a passion that stayed with me through my education in biology and veterinary medicine. As for the interface, I think it just seemed obvious to me that all these different biological organisms, including us, are interconnected and that it makes sense to look at them in an ensemble. In the past two hundred years or so, the development of different medical specializations has discouraged cross-disciplinary thinking




William Karesh

William B Karesh is an internationally recognized authority on “One Health”, an integrated approach to animal, human and environmental health. He has pioneered One Health initiatives in over 45 countries and has worked to reduce the impact of diseases such as Ebola, measles and tuberculosis on humans and animals including gorillas and chimpanzees. Executive Vice President for Health and Policy at EcoHealth Alliance, Karesh is also president of the World Organisation for Animal Health Working Group on Wildlife and an expert on the World Health Organization (WHO)’s International Health Regulations Roster of Experts focused on the human-animal interface and wildlife health. Author of over 200 peer-reviewed articles and numerous book chapters, he received a Bachelor of Science in biology from Clemson University in South Carolina, United States of America in 1977, and a doctorate in veterinary medicine from the University of Georgia, South Carolina in 1982.


**KARESH
ECOHEALTH ALLIANCE
ONE HEALTH**

100 DAYS AGENDA

The collage consists of five video player screenshots arranged in a grid-like layout. Each screenshot shows a different panel discussion or speaker. The top-left video is titled 'WS 29 - Getting to the 100 Day Mission for Better Pandemic Preparedness' and features a panel of three men. The top-right video is a tweet from Chikwe Ihekweazu (@Chikwe_I) dated Sep 24, 2020, replying to @Chikwe_I, discussing the mission. The middle-left video is 'CEPI's 100 day Mission with Melanie Saville | WIRED Health' featuring a woman speaking. The middle-right video is '100 days to outrace the next pandemic | Davos 2023' featuring a panel of four people. The bottom-left video is 'Global Citizen Explains | How Can a New Vaccine Be Created in 100 Days?' featuring a man in a suit. The bottom-right video is a tweet from UK at the UN (@UKattheUN) dated Mar 10, 2022, about the Global Pandemic Preparedness Summit.



The screenshot shows the WHO COP28 Health Pavilion website. At the top, there is a photo of a conference room with a blue table and chairs. To the right is the large WHO logo. Below the photo, the text "COP28 Health Pavilion" is displayed. The main content area has a blue header with the date "30 November – 12 December 2023 | Dubai, United Arab Emirates". Below this, a paragraph of text describes the Health Pavilion's purpose and activities. A large, stylized "Upcoming Dates" heading is centered on the page. To the right, there is a section titled "High-level meetings" with two entries: "20 September 2023 | Pandemic prevention, preparedness and response" and "21 September 2023 | Universal health coverage". Each entry includes a brief description and a bulleted list of agenda items.



The screenshot shows the cover of the "CEPI Delivering Pandemic Vaccines in 100 Days" report. The cover features a dark blue background with a yellow circular graphic on the left. The title "CEPI" is at the top, followed by "Delivering Pandemic Vaccines in 100 Days" in large white and yellow text. Below the title is the date "December 2022^". To the right of the title is a diagram titled "A new paradigm for vaccine development for outbreak response". The diagram is a timeline with four main phases: "Pre-outbreak" (red), "Between outbreak & initial vaccine availability" (yellow), "Point of outbreak" (red), and "Available for use" (blue). Below the timeline, there are descriptions for each phase. To the right of the timeline is a section titled "An enabling policy and financing context" with two columns of text. The first column discusses the challenges of implementing scientific and technological innovations, while the second column discusses the global response to COVID-19 and its challenges.

19  I haven't even begun on the Disease Surveillance apparatus that they are trying to implement globally and how all these people are names you WILL see again in regards to your health freedoms. Receipts are on the slides. #NoOneHealth #stopthetreaty

EIOS = EPIDEMIC INTELLIGENCE FROM OPEN SOURCES
WHO=WORLD HEALTH ORGANIZATION
HDRAS = HAZARD DETECTION AND RISK ASSESSMENT
JRC=JOINT RESEARCH CENTRE
EAR=EARLY ALERTING AND REPORTING
EC=EUROPEAN COMMISSION
WOAH=WORLD ORGANIZATION FOR ANIMAL HEALTH
PAHO= PAN AMERICAN HEALTH ORGANIZATION
GPHIN= GLOBAL PUBLIC HEALTH INTELLIGENCE NETWORK
GHIF= GLOBAL HEALTH INVESTMENT FUND [2012]
GHIC=GLOBAL HEALTH INVESTMENT CORPORATION
GHSA=GLOBAL HEALTH SECURITY AGENDA
GPMB=GLOBAL PREPAREDNESS MONITORING BOARD
IAVI- INTERNATIONAL AIDS VACCINE INITIATIVE [1996]
GAVI=GLOBAL ALLIANCE FOR VACCINES AND IMMUNIZATION [2000]
CEPI- COALITION FOR EPIDEMIC PREPAREDNESS INNOVATION [2017]
DHIS2- DISTRICT HEALTH INFORMATION SYSTEM 2 [2006 EU]
HISP= HEALTH INFORMATION SOFTWARE PLATFORM
UN=UNITED NATIONS, USG= UNITED STATES GOV EU-EURO UNION
EC= EUROPEAN COMMISSION

Important

ABBREVIATIONS

that YOU should know !

World Health Organization

Home / Newsroom / Events / Detail / Strategic Advisory Group of Experts on Immunization (SAGE) - September 2023

Strategic Advisory Group of Experts on Immunization (SAGE) - September 2023

25 – 29 September 2023

This meeting for the Strategic Advisory Group of Experts on Immunization (SAGE) will be held from Monday to Friday inclusive.

How do I register ?

Participation at the meeting is by invitation only. If you have not received an invitation email and would like to attend, please contact: sagesecsec@who.int

Where is the meeting?

The meeting is planned to take place at WHO HQ. More details to follow.

Where can I stay during the meeting?

A list of accommodation options are available from sagesecsec@who.int and will be communicated to you upon registration approval.

Meeting materials

Materials for this meeting such as a draft agenda, provisional list of participants and background documents will be made available nearer the time.

Are there any upcoming events or conferences organized by the WHO in 2023

Quick Search

Events - World Health Organization (WHO) [who](#) - 1

Events from August 2 - Global Health Council [globalhealth](#) - 2

WHO Meetings - European Society for... [esmo](#) - 3

Event: 76th World Health Assembly | SDG... [led](#) - 4

2023 Event Trends You Need to Know - Blog - [bconnext](#) - 5

Halfway Through 2023 - How is Your Event... [linkedin](#) - 6

Answer

According to the search results, there are a few upcoming events and conferences organized by the World Health Organization (WHO) in 2023:

1. COP28 Health Pavilion - November 30, 2023
2. Fourth WHO Global School on Refugee and Migrant Health - November 27, 2023

Please note that these are the specific events mentioned in the search results. It's possible that there may be additional events or conferences organized by the WHO in 2023 that are not listed in the search results. For more comprehensive and up-to-date information, it is recommended to visit the official WHO website or contact the WHO directly.

WHO *Upcoming Dates*


CEPI has an ambitious \$3.5 billion equitable-access focussed R&D plan that will help the world create safe and effective vaccines in 100 days...

That changed in response to SARS-CoV-2: the world rallied together and managed to produce a safe and effective vaccine in just 326 days.



CEPI

#100DAYSMISSION



CEPI

ARCHITECTS OF CHANGE

100 Days

November 29, 2020

SHARE

Developing pandemic-busting vaccines in 100 days

By Dr Richard Hatchett

The world can face down the next Disease X with a new vaccine in just 100 days. Here's how...

CEPI

Had these kinds of milestones been achieved for a *single* COVID-19 vaccine candidate, then a safe and effective vaccine could in theory have been available for use, based on Phase 3 results, more than two months sooner than in this pandemic. That would have shortened the time from "lab to jab" or from the publication of a genetic sequence to getting a new vaccine into arms, to less than 9 months. And that's without any change to our current regulatory paradigm.

What's possible now

If we look across the global portfolio of COVID-19 vaccines—life-saving products that were created from scratch, then manufactured, tested, trialled and brought to bear against a completely new disease—many fast-paced possibilities are clear:

- It's possible to design a vaccine candidate within 2 days of the genetic sequence of a new virus being published. We know, because that's what the NIAID Vaccine Research Center did.
- It's possible to move into first human trials in 66 days from the release of the genetic sequence. We know, because that's what Moderna did.
- It's possible to publish the first safety data 63 days after a Phase 1 clinical trial starts. We know, because that's what Moderna did.
- It's possible to go from first human clinical trials to vaccine registration in about 7 months. We know, because that's what Pfizer / BioNTech did.
- And it's possible to get emergency use approval within 1 day of filing required data with regulators. We know, because that's what China's CanSino did.

Link: <https://100days.cepi.net/100-days/>

@carolina_bonita @P_McCulloughMD @US_FDA @NIH @Jikkyleaks @HouseLyndsey @JenLawrence21 @WeAre32937 @jathorpmfm @JeffereyJaxen @7777rep @RandPaul @nic_moneypenny @whitematador @mikemactv @TheRedactedInc @Nuni_Sas_Yu @FrauHodl @Oneiam82 @StealthMedical1

@threadreaderapp unroll this thread

• • •